Free Trial
NASDAQ:AZN

AstraZeneca (AZN) Stock Price, News & Analysis

AstraZeneca logo
$85.31 +1.66 (+1.98%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$85.32 +0.02 (+0.02%)
As of 10/3/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AstraZeneca Stock (NASDAQ:AZN)

Advanced

Key Stats

Today's Range
$83.84
$85.50
50-Day Range
$71.83
$85.31
52-Week Range
$61.24
$85.50
Volume
5.87 million shs
Average Volume
4.94 million shs
Market Capitalization
$264.58 billion
P/E Ratio
32.07
Dividend Yield
1.18%
Price Target
$86.00
Consensus Rating
Moderate Buy

Company Overview

AstraZeneca Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
60th Percentile Overall Score

AZN MarketRank™: 

AstraZeneca scored higher than 60% of companies evaluated by MarketBeat, and ranked 422nd out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.

  • Upside/Downside

    The consensus price target for AstraZeneca is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    AstraZeneca has only been the subject of 1 research reports in the past 90 days.

  • Read more about AstraZeneca's stock forecast and price target.
  • Earnings Growth

    Earnings for AstraZeneca are expected to grow by 10.86% in the coming year, from $4.51 to $5.00 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AstraZeneca is 32.07, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 222.70.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AstraZeneca is 32.07, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 65.27.

  • Price to Earnings Growth Ratio

    AstraZeneca has a PEG Ratio of 1.57. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    AstraZeneca has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AstraZeneca's valuation and earnings.
  • Percentage of Shares Shorted

    0.25% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 0.39%, indicating that investor sentiment is improving.
  • Dividend Yield

    AstraZeneca pays a meaningful dividend of 1.18%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    AstraZeneca does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of AstraZeneca is 37.97%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, AstraZeneca will have a dividend payout ratio of 20.20% next year. This indicates that AstraZeneca will be able to sustain or increase its dividend.

  • Read more about AstraZeneca's dividend.
  • Percentage of Shares Shorted

    0.25% of the outstanding shares of AstraZeneca have been sold short.
  • Short Interest Ratio / Days to Cover

    AstraZeneca has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AstraZeneca has recently decreased by 0.39%, indicating that investor sentiment is improving.
  • News Sentiment

    AstraZeneca has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 29 news articles for AstraZeneca this week, compared to 23 articles on an average week.
  • Search Interest

    34 people have searched for AZN on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added AstraZeneca to their MarketBeat watchlist in the last 30 days. This is an increase of 71% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AstraZeneca insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 20.35% of the stock of AstraZeneca is held by institutions.

  • Read more about AstraZeneca's insider trading history.
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AZN Stock News Headlines

URGENT: The Market's 3 Red Flags Are Flashing
The warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.tc pixel
See More Headlines

AZN Stock Analysis - Frequently Asked Questions

AstraZeneca's stock was trading at $65.52 at the beginning of the year. Since then, AZN stock has increased by 30.2% and is now trading at $85.31.

AstraZeneca PLC (NASDAQ:AZN) issued its quarterly earnings data on Tuesday, July, 29th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. The firm's revenue for the quarter was up 16.1% on a year-over-year basis.
Read the conference call transcript
.

AstraZeneca shares split on Monday, July 27th 2015.The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were issued to shareholders after the closing bell on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

The following companies are subsidiaries of AstraZeneca: Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

Top institutional investors of AstraZeneca include Park National Corp OH (0.01%), Aaron Wealth Advisors LLC, GAMMA Investing LLC and Capital Asset Advisory Services LLC.
View institutional ownership trends
.

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Chevron (CVX), BlackRock (BLK), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Bristol Myers Squibb (BMY) and Tesla (TSLA).

Company Calendar

Last Earnings
7/29/2025
Record date for 9/8 Dividend
8/08/2025
Ex-Dividend for 9/8 Dividend
8/08/2025
Dividend Payable
9/08/2025
Today
10/05/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AZN
CIK
901832
Employees
94,300
Year Founded
1999

Price Target and Rating

High Price Target
$97.00
Low Price Target
$75.00
Potential Upside/Downside
+0.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
$2.66
Trailing P/E Ratio
32.07
Forward P/E Ratio
18.92
P/E Growth
1.57
Net Income
$7.04 billion
Net Margins
14.68%
Pretax Margin
17.74%
Return on Equity
32.84%
Return on Assets
12.87%

Debt

Debt-to-Equity Ratio
0.55
Current Ratio
0.86
Quick Ratio
0.67

Sales & Book Value

Annual Sales
$54.07 billion
Price / Sales
4.89
Cash Flow
$6.30 per share
Price / Cash Flow
13.55
Book Value
$13.18 per share
Price / Book
6.47

Miscellaneous

Outstanding Shares
3,101,390,000
Free Float
N/A
Market Cap
$264.58 billion
Optionable
Optionable
Beta
0.36

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:AZN) was last updated on 10/5/2025 by MarketBeat.com Staff
From Our Partners